Search for dissertations about: "177Lu-octreotate"

Showing result 1 - 5 of 9 swedish dissertations containing the word 177Lu-octreotate.

  1. 1. Dosimetry of Radionuclide Therapy with 177Lu-octreotate

    University dissertation from Uppsala : Acta Universitatis Upsaliensis

    Author : Mattias Sandström; Uppsala universitet.; [2011]
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; 177Lu-octreotate; Absorbed dose; Neuroendocrine tumour; Medicinsk radiofysik; Medical Radiophysics;

    Abstract : In radionuclide therapy it is still common to administer standard activities or to scale administered activity with blunt parameters such as body weight or surface area. This is not ideal because, due to considerable variation in kinetics, large safety margins have to be applied to avoid radiation damage to healthy organs, which causes under-treatment of many patients. READ MORE

  2. 2. Multiparametric MRI for evaluation of tumour treatment response Studies of 177Lu-octreotate therapy of neuroendocrine tumour

    University dissertation from Uppsala : Acta Universitatis Upsaliensis

    Author : Mikael Montelius; Göteborgs universitet.; Gothenburg University.; [2016]
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Cancer; Functional imaging; IVIM; MRI; DWI; DCE; histology; 177Lu-octreotate; small intestine neuroendocrine tumour; NET; diffusion; perfusion; semi-quantitative; proteomics; ionizing radiation; biology; imaging biomarker;

    Abstract : Clinical assessment of tumour response to treatment largely relies on estimates of tumour size by, e.g., measuring the largest tumour diameters on magnetic resonance (MR) or computed tomography (CT) images, weeks or months after treatment. READ MORE

  3. 3. Therapy with 177Lu-octreotate - pharmacokinetics, dosimetry and kidney toxicity

    University dissertation from Göteborg : University of Gothenburg

    Author : Maria Larsson; Göteborgs universitet.; Gothenburg University.; [2014]
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; PRRT; 177Lu-octreotate; 111In-octreotide; dosimetry; biokinetics; scintigraphy; conjugate view method; renal function; renal toxicity; lysine; DMSA; 99mTc-DTPA; 99mTc-DMSA;

    Abstract : 177Lu-octreotate is used for treatment of patients with somatostatin receptor expressing neuroendocrine tumors in some clinics using a standard schedule. Renal and bone marrow toxicity are the main limiting factors. READ MORE

  4. 4. Therapy of neuroendocrine tumors with 177Lu-octreotate - Human tumor cell types and models and optimization of treatment Terapi av neuroendokrina tumörer med 177Lu-octreotate

    University dissertation from Göteborg : University of Gothenburg

    Author : Johanna Dalmo; Göteborgs universitet.; Gothenburg University.; Göteborgs universitet.; Gothenburg University.; [2014]
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; somatostatin; radionuclide therapy; receptor up-regulation; RBP; nephrotoxicity;

    Abstract : Neuroendocrine (NE) tumors (NET) have often metastasized at the time of diagnose, which makes it hard to cure patients with NET. Radiolabeled hormone analogues (especially somatostatin analogues, SS) can be used for diagnostics (e.g. 111In-octreotide) and therapy (e. READ MORE

  5. 5. Biomarker discovery and assessment for prediction of kidney response after 177Lu-octreotate therapy

    University dissertation from Göteborg : University of Gothenburg

    Author : Emil Schüler; Göteborgs universitet.; Gothenburg University.; [2014]
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; PRRT; somatostatin; radionuclide therapy; 177Lu-octreotate; scintigraphy; renal function; toxicity; kidney response; radiation biology; microarray; molecular biomarkers; ionizing radiation; miRNA; proteomics; transcriptional response;

    Abstract : Patients suffering from neuroendocrine tumors are oftentimes presented with spread disease at the time of diagnosis. Therapy using somatostatin analogs is today the only potentially curative treatment option for these patients. READ MORE